These findings suggest that HMGB1 may be an important mediator in NAFLD and that inhibition of HMGB1 may represent a potential approach for anti-inflammatory therapy of NAFLD. The gene discussed is HMGB1; the disease is metabolic dysfunction-associated steatotic liver disease.